DRC Bundibugyo Ebola Trial Begins: Searching for the First Treatment Answers at the Outbreak Site

In an Ebola outbreak, time is often harsher than the laboratory. Patients may arrive at treatment centers only after fever, vomiting, and bleeding symptoms have worsened; health care workers provide isolated care while facing community concerns and security risks. Now, the Bundibugyo virus outbreak in eastern Democratic Republic of the Congo has finally enrolled the first participant in a key treatment trial, giving this less-studied Ebola virus subtype a chance to accumulate more direct human evidence.

The World Health Organization announced that the study has begun at the Ebola treatment center at the Evangelical Medical Center in Bunia, Ituri Province. The trial will assess whether the antiviral drug remdesivir, Mapp Biopharmaceutical’s experimental antibody therapy MBP134, and the two used in combination can improve survival among people infected with Bundibugyo virus, in addition to standard supportive care. The primary endpoint is survival 28 days after the start of treatment.

The importance of the study comes from a clinical gap: there is already vaccine and treatment experience for Zaire ebolavirus, but Bundibugyo virus has no confirmed specific therapy or vaccine. Supportive care, including fluid replacement, electrolyte maintenance, management of complications, and early referral for care, remains an important foundation for whether patients can survive the acute phase. The new trial aims to answer whether, on top of that care, existing or experimental drugs can push the risk of death lower.

The study is being carried out through cooperation among the Democratic Republic of the Congo’s National Institute of Biomedical Research, the University of Oxford, the Institute of Tropical Medicine Antwerp, the World Health Organization, and multiple international partners. According to the Associated Press, citing WHO research adviser Vasee Moorthy, the trial may need several months and as many as about 1,000 participants to obtain a clear answer; researchers on the Congolese side estimate that actual progress may continue for three to six months depending on how the outbreak evolves. These numbers are not guarantees, but reflect how infectious disease clinical trials are often shaped by case numbers, timing of care-seeking, and access on the ground.

At the start, the trial can take place in only a single treatment center, not because the scientific question has been simplified, but because field conditions do not yet allow a larger rollout. Eastern Congo has long been affected by armed conflict and displacement. Crowded medical facilities, patients delaying care, and community mistrust of outside outbreak-response teams could all affect recruitment, follow-up, and quality of care. The research team said the trial will expand to more treatment sites in the future if security conditions allow.

Background Context

Before the trial began, researchers had already described this Partners trial as a framework for finding the best treatment strategy for Bundibugyo Ebola; candidate drugs discussed earlier included MBP134, maftivimab, and remdesivir. Another prevention-focused study is also being planned, potentially using the oral antiviral candidate obeldesivir for contacts of confirmed cases. However, between candidate drugs and an executable trial lie multiple hurdles, including regulatory approval, drug logistics, infection control, and security deployment.

The next answers may not come quickly. If the outbreak eases, the study may become difficult to interpret because of insufficient cases; if the outbreak continues to expand, clinical care and research execution will come under greater pressure. For that reason, this launch is itself an important turning point: it moves Bundibugyo virus treatment from speculation, animal data, and extrapolated experience toward the stage of collecting human evidence at the center of an outbreak.